Cargando…

Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients

Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunes, Fabio P., Merker, Vanessa L., Jennings, Dominique, Caruso, Paul A., di Tomaso, Emmanuelle, Muzikansky, Alona, Barker, Fred G., Stemmer-Rachamimov, Anat, Plotkin, Scott R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605344/ https://www.ncbi.nlm.nih.gov/pubmed/23555840 http://dx.doi.org/10.1371/journal.pone.0059941

Ejemplares similares

Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
por: Jordan, Justin T, et al.
Publicado: (2023)

Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas
por: Shen, Yiping, et al.
Publicado: (2009)

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas
por: Beauchamp, Roberta L., et al.
Publicado: (2015)

Natural History of Meningioma Development in Mice Reveals: A Synergy of Nf2 and p16 (Ink4a) Mutations
por: Kalamarides, Michel, et al.
Publicado: (2007)

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
por: Vaios, Eugene J, et al.
Publicado: (2020)

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
por: Mathew Thomas, Vinay, et al.
Publicado: (2019)

Correction to: An update on the CNS manifestations of neurofibromatosis type 2
por: Coy, Shannon, et al.
Publicado: (2019)

An update on the CNS manifestations of neurofibromatosis type 2
por: Coy, Shannon, et al.
Publicado: (2019)

Decreased Vision and Junctional Scotoma from Pituicytoma
por: Huynh, Nancy, et al.
Publicado: (2012)

Genomic landscape of high-grade meningiomas
por: Bi, Wenya Linda, et al.
Publicado: (2017)

Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis
por: Plotkin, Scott R., et al.
Publicado: (2012)

Erratum: Genomic landscape of high-grade meningiomas
por: Bi, Wenya Linda, et al.
Publicado: (2017)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Spontaneous rupture of an arachnoid cyst in an adult: illustrative case
por: Leavitt, Lydia A., et al.
Publicado: (2023)

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK
por: Chang, Long-Sheng, et al.
Publicado: (2021)

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
por: Brastianos, Priscilla K., et al.
Publicado: (2013)

Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic
por: Williams, Erik A., et al.
Publicado: (2020)

Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter]
por: da Silva, Vinicius Trindade Gomes, et al.
Publicado: (2022)

A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura
por: Goreshnik, Ashley, et al.
Publicado: (2020)

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma
por: Kumthekar, Priya, et al.
Publicado: (2022)

Nf1 Loss and Ras Hyperactivation in Oligodendrocytes Induce NOS-Driven Defects in Myelin and Vasculature
por: Mayes, Debra A., et al.
Publicado: (2013)

Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report
por: Li, Jennifer Chen, et al.
Publicado: (2022)

Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study
por: Bai, Xuexue, et al.
Publicado: (2022)

Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas
por: Kukutla, Phanidhar, et al.
Publicado: (2021)

Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review
por: Franke, Aaron J., et al.
Publicado: (2018)

Clinical factors associated with massive pulmonary embolism and PE-related adverse clinical events
por: Hariharan, Praveen, et al.
Publicado: (2021)

Using magnetic resonance microscopy to study the growth dynamics of a glioma spheroid in collagen I: A case study
por: Huang, Shuning, et al.
Publicado: (2008)

IgG4-Related Disease and Hypertrophic Pachymeningitis
por: Wallace, Zachary S., et al.
Publicado: (2013)

Are neurofibromatosis type 1 (NF1) patients at increased risk of meningioma and in particular malignant meningioma?
por: Evans, D. Gareth R., et al.
Publicado: (2022)

The Role of Merlin/NF2 Loss in Meningioma Biology
por: Lee, Sungho, et al.
Publicado: (2019)

Full Recovery after Multiple Treatments with Injectable Ice Slurry
por: Moradi Tuchayi, Sara, et al.
Publicado: (2022)

Fast-acting and injectable cryoneurolysis device
por: Moradi Tuchayi, Sara, et al.
Publicado: (2022)

Fluorescence Polarization of Methylene Blue as a Quantitative Marker of Breast Cancer at the Cellular Level
por: Yaroslavsky, Anna N., et al.
Publicado: (2019)

A pilot mixed‐methods randomized controlled trial of verbal versus electronic screening for adverse social determinants of health
por: Macias‐Konstantopoulos, Wendy, et al.
Publicado: (2022)

Comparative Transcriptomic Analysis of Archival Human Vestibular Schwannoma Tissue from Patients with and without Tinnitus
por: Bommakanti, Krishna, et al.
Publicado: (2023)

MENINGIOMA-01 HISTOPATHOLOGICAL PATTERN OF MENINGIOMA IN IBADAN, SOUTHWEST NIGERIA: A 15-YEAR RETROSPECTIVE STUDY
por: Ogunsanya, Temitope
Publicado: (2023)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Isolated Extracranial Intraosseous Metastasis of an Intracranial Meningioma following Bevacizumab Therapy: Case Report and Review of the Literature
por: Mukherjee, Debraj, et al.
Publicado: (2018)

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition
por: Beauchamp, Roberta L., et al.
Publicado: (2020)

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma
por: Plotkin, Scott R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gtpk7q6q377dsmt97nnblm3qak